GHRH and cancer: A recent study investigated the diagnostic accuracy of the GHRH+Arginine test concluding that it should provide specific cut-off points depending on the pathological condition, such as congenital GHD, isolated GHD, multiple pituitary hormone defects and cancer survivors (17).